MX2019008690A - Compuestos espiro heterociclicos como inhibidores de magl. - Google Patents
Compuestos espiro heterociclicos como inhibidores de magl.Info
- Publication number
- MX2019008690A MX2019008690A MX2019008690A MX2019008690A MX2019008690A MX 2019008690 A MX2019008690 A MX 2019008690A MX 2019008690 A MX2019008690 A MX 2019008690A MX 2019008690 A MX2019008690 A MX 2019008690A MX 2019008690 A MX2019008690 A MX 2019008690A
- Authority
- MX
- Mexico
- Prior art keywords
- spiro compounds
- heterocyclic spiro
- magl inhibitors
- compounds
- preparation
- Prior art date
Links
- -1 Heterocyclic spiro compounds Chemical class 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 102100029814 Monoglyceride lipase Human genes 0.000 abstract 1
- 101710116393 Monoglyceride lipase Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762449242P | 2017-01-23 | 2017-01-23 | |
| PCT/IB2018/050128 WO2018134698A1 (en) | 2017-01-23 | 2018-01-09 | Heterocyclic spiro compounds as magl inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019008690A true MX2019008690A (es) | 2019-09-18 |
Family
ID=61028112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019008690A MX2019008690A (es) | 2017-01-23 | 2018-01-09 | Compuestos espiro heterociclicos como inhibidores de magl. |
Country Status (14)
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6832914B2 (ja) | 2015-07-31 | 2021-02-24 | ファイザー・インク | Ｍａｇｌ阻害薬としての１，１，１−トリフルオロ−３−ヒドロキシプロパン−２−イルカルバマート誘導体および１，１，１−トリフルオロ−４−ヒドロキシブタン−２−イルカルバマート誘導体 |
| JP7106462B2 (ja) | 2016-07-01 | 2022-07-26 | ジー１ セラピューティクス， インコーポレイテッド | Ｎ－（ヘテロアリール）－ピロロ［３，２－ｄ］ピリミジン－２－アミンの合成 |
| CA3050625C (en) * | 2017-01-20 | 2021-07-20 | Pfizer Inc. | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors |
| US10927105B1 (en) | 2017-05-23 | 2021-02-23 | Lundbeck La Jolla Research Center, Inc. | Pyrazole MAGL inhibitors |
| CA3076477A1 (en) * | 2017-09-29 | 2019-04-04 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| US10662159B2 (en) * | 2017-11-22 | 2020-05-26 | Makscientific, Llc | ABHD6 and dual ABHD6/MGL inhibitors and their uses |
| CN111566105A (zh) | 2018-01-08 | 2020-08-21 | 豪夫迈·罗氏有限公司 | 作为MAGL抑制剂的八氢吡啶并[1,2-α]吡嗪类化合物 |
| US20210309669A1 (en) * | 2018-07-19 | 2021-10-07 | Pfizer Inc. | Heterocyclic Spiro Compounds As MAGL Inhibitors |
| EP3840756B1 (en) | 2018-08-24 | 2025-11-05 | Pharmacosmos Holding A/S | Improved synthesis of 1,4-diazaspiro[5.5]undecan-3-one |
| EP3856179A1 (en) * | 2018-09-28 | 2021-08-04 | Janssen Pharmaceutica N.V. | Monoacylglycerol lipase modulators |
| JP2022509206A (ja) * | 2018-11-28 | 2022-01-20 | ハー・ルンドベック・アクチエゼルスカベット | Ｍａｇｌ阻害剤による疾病の治療方法 |
| CN109485656A (zh) * | 2018-12-17 | 2019-03-19 | 上海药明康德新药开发有限公司 | 3-氧亚基-7-氧杂-2,10-二氮杂螺[4.6]十一烷-10-甲酸叔丁酯的制法 |
| MX2021008865A (es) * | 2019-01-25 | 2021-10-26 | H Lundbeck As | Inhibidores de magl para usarse para tratar enfermedades antecedentes. |
| CN114096545A (zh) * | 2019-07-09 | 2022-02-25 | 豪夫迈·罗氏有限公司 | 新杂环化合物 |
| AU2020358948A1 (en) | 2019-09-30 | 2022-05-26 | Janssen Pharmaceutica Nv | Radiolabelled MGL PET ligands |
| KR20220158785A (ko) * | 2020-03-26 | 2022-12-01 | 얀센 파마슈티카 엔.브이. | 모노아실글리세롤 리파아제 조절제로서의 아미노사이클로부탄 |
| WO2021228123A1 (zh) * | 2020-05-12 | 2021-11-18 | 北京广为医药科技有限公司 | 调节nmda受体活性的化合物、其药物组合物及用途 |
| ES2997114T3 (en) * | 2020-09-22 | 2025-02-14 | Janssen Pharmaceutica Nv | Cyclobutyl amide monoacylglycerol lipase modulators |
| US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
| US11434222B2 (en) * | 2020-11-13 | 2022-09-06 | H. Lundbeck A/S | MAGL inhibitors |
| WO2022135462A1 (zh) * | 2020-12-22 | 2022-06-30 | 鲁南制药集团股份有限公司 | Magl抑制剂的医药用途 |
| KR20240128870A (ko) | 2021-12-29 | 2024-08-27 | 싸이 테라퓨틱스, 인크. | 모노아실글리세롤 리파아제(magl) 억제 |
| AU2023264787A1 (en) * | 2022-05-04 | 2024-10-31 | H. Lundbeck A/S | Crystalline form of 1,1,1,3,3,3-hexafluoropropan-2-yl (s)-1-(pyridazin-3-ylcarbamoyl)-6 azaspiro[2.5]octane-6-carboxylate as monoacylglycerol lipase inhibitor. |
| WO2024168426A1 (en) | 2023-02-13 | 2024-08-22 | Apogee Pharmaceuticals, Inc. | Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0273659A1 (en) | 1986-12-27 | 1988-07-06 | Takeda Chemical Industries, Ltd. | Azaspiro compounds, their production and use |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| AU699272B2 (en) | 1994-08-02 | 1998-11-26 | Merck Sharp & Dohme Limited | Azetidine, pyrrolidine and piperidine derivatives |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| CA2369695A1 (en) | 1999-04-09 | 2000-10-19 | Manabu Itoh | Agent for treating neuropathic pain |
| WO2001011968A2 (en) | 1999-08-13 | 2001-02-22 | Aventis Cropscience Gmbh | Heterocyclic spiro compounds as pesticides |
| US20020151712A1 (en) | 1999-09-14 | 2002-10-17 | Nan-Horng Lin | 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission |
| US6696443B2 (en) | 2000-11-20 | 2004-02-24 | Scios, Inc. | Piperidine/piperazine-type inhibitors of p38 kinase |
| DK1390372T3 (da) | 2001-05-14 | 2008-09-15 | Hoffmann La Roche | 1-oxa-3,9-diaza-spiro '5,5]undecan-2-on-derivater og anvendelse deraf som neurokininreceptorantagonist |
| GEP20084393B (en) | 2003-04-24 | 2008-06-10 | Incyte Corp | Aza spiro alkane derivatives as inhibitors of metalloproteases |
| NZ545748A (en) | 2003-08-29 | 2010-03-26 | Ranbaxy Lab Ltd | Isoxazoline derivatives as inhibitors of phosphodiesterase type-IV |
| SE0302811D0 (sv) | 2003-10-23 | 2003-10-23 | Astrazeneca Ab | Novel compounds |
| AR046756A1 (es) | 2003-12-12 | 2005-12-21 | Solvay Pharm Gmbh | Derivados de hidronopol como agonistas de receptores orl-1 humanos. |
| JP3912400B2 (ja) | 2004-03-30 | 2007-05-09 | 株式会社デンソー | 圧力センサ |
| ES2370788T3 (es) | 2005-02-07 | 2011-12-22 | Aerocrine Ab | Controlar flujo de aliento exhalado durante análisis. |
| BRPI0611498B1 (pt) | 2005-05-25 | 2015-10-13 | Basf Ag | composto, processos para a preparação de compostos e de agentes, e para combater vegetação indesejada, agente, e, uso de compostos |
| EP1888509B1 (de) | 2005-05-25 | 2013-05-15 | Basf Se | Benzoylsubstituierte serin-amide |
| BRPI0613505A2 (pt) | 2005-06-30 | 2011-01-11 | Prosidion Ltd | agonistas de gpcr |
| AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
| ES2483866T3 (es) | 2006-12-05 | 2014-08-08 | Janssen Pharmaceutica Nv | Derivados de diaza-espiro-piridinona sustituidos novedosos para uso en enfermedades mediadas por MCH-1 |
| FR2915198B1 (fr) | 2007-04-18 | 2009-12-18 | Sanofi Aventis | Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique. |
| JP2010524940A (ja) | 2007-04-20 | 2010-07-22 | シェーリング コーポレイション | ピリミジノン誘導体およびそれらの使用方法 |
| EP2058306A1 (en) | 2007-11-08 | 2009-05-13 | Schwarz Pharma Ag | Heteroaryl-substituted 2-pyridinyl-methylamine derivatives |
| MX2011000664A (es) | 2008-07-16 | 2011-02-24 | Schering Corp | Derivados biciclicos heterociclicos y uso de los mismos como moduladores de gpr119. |
| JP2012506883A (ja) | 2008-10-29 | 2012-03-22 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 置換されたスピロアミン |
| CA2743861A1 (en) | 2008-11-14 | 2010-05-20 | The Scripps Research Institute | Methods and compositions related to targeting monoacylglycerol lipase |
| BRPI0923819B1 (pt) * | 2008-12-24 | 2021-11-09 | Bial-Portela & Ca, S.A. | Compostos inibidores de hidrolase amida de ácidos graxos, composições e usos dos mesmos |
| US8435977B2 (en) | 2009-04-22 | 2013-05-07 | Janssen Pharmaceutica, Nv | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors |
| TWI465446B (zh) | 2009-04-22 | 2014-12-21 | Janssen Pharmaceutica Nv | 作為單醯基甘油脂酶抑制劑之吖丁啶基二醯胺類（四） |
| FR2945531A1 (fr) | 2009-05-12 | 2010-11-19 | Sanofi Aventis | Derives de 7-aza-spiro°3,5!nonane-7-carboxylates, leur preparation et leur application en therapeutique |
| JPWO2011142359A1 (ja) | 2010-05-10 | 2013-07-22 | 日産化学工業株式会社 | スピロ化合物及びアディポネクチン受容体活性化薬 |
| FR2960875B1 (fr) | 2010-06-04 | 2012-12-28 | Sanofi Aventis | Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique |
| JP2013537920A (ja) | 2010-09-27 | 2013-10-07 | ヤンセン ファーマシューティカ エヌ．ベー． | モノアシルグリセロールリパーゼ阻害剤としてのオキソピペラジン−アゼチジンアミド及びオキソジアゼピン−アゼチジンアミド |
| US8513423B2 (en) | 2010-10-22 | 2013-08-20 | Janssen Pharmaceutica, Nv | Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors |
| US8575363B2 (en) | 2010-10-22 | 2013-11-05 | Janssen Pharmaceutica N.V. | Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors |
| ES2618929T3 (es) | 2011-03-14 | 2017-06-22 | Vertex Pharmaceuticals Incorporated | Morfolina-Spiro piperidina amida cíclica como moduladores del canal iónico |
| JP2014159376A (ja) | 2011-06-17 | 2014-09-04 | Taisho Pharmaceutical Co Ltd | アザスピロアルカン化合物 |
| ES2982694T3 (es) * | 2012-01-06 | 2024-10-17 | H Lundbeck As | Compuestos de carbamato para su uso en tratamiento |
| WO2013131010A2 (en) | 2012-03-02 | 2013-09-06 | Icahn School Of Medicine At Mount Sinai | Function of chemokine receptor ccr8 in melanoma metastasis |
| JP6566867B2 (ja) | 2012-07-13 | 2019-08-28 | ペイン セラピューティクス インコーポレイテッド | 生きている患者でのアルツハイマー病アッセイ |
| WO2014074715A1 (en) | 2012-11-07 | 2014-05-15 | Genentech, Inc. | Cyclopropyl amide derivatives |
| WO2015104343A1 (en) | 2014-01-09 | 2015-07-16 | Proyecto De Biomedicina Cima, S.L. | New antifibrinolytic compounds |
| US9771341B2 (en) * | 2015-03-18 | 2017-09-26 | Abide Therapeutics, Inc. | Piperazine carbamates and methods of making and using same |
| JP6832914B2 (ja) | 2015-07-31 | 2021-02-24 | ファイザー・インク | Ｍａｇｌ阻害薬としての１，１，１−トリフルオロ−３−ヒドロキシプロパン−２−イルカルバマート誘導体および１，１，１−トリフルオロ−４−ヒドロキシブタン−２−イルカルバマート誘導体 |
| US10030020B2 (en) * | 2016-05-12 | 2018-07-24 | Abide Therapeutics, Inc. | Spirocycle compounds and methods of making and using same |
-
2018
- 2018-01-09 CN CN201880007992.7A patent/CN110198944A/zh active Pending
- 2018-01-09 BR BR112019014099-9A patent/BR112019014099A2/pt not_active Application Discontinuation
- 2018-01-09 RU RU2019123020A patent/RU2726631C1/ru active
- 2018-01-09 CA CA3050853A patent/CA3050853A1/en not_active Abandoned
- 2018-01-09 EP EP18701578.9A patent/EP3571202B1/en active Active
- 2018-01-09 KR KR1020197021451A patent/KR20190097242A/ko not_active Withdrawn
- 2018-01-09 AU AU2018208848A patent/AU2018208848A1/en not_active Abandoned
- 2018-01-09 WO PCT/IB2018/050128 patent/WO2018134698A1/en not_active Ceased
- 2018-01-09 MX MX2019008690A patent/MX2019008690A/es unknown
- 2018-01-09 SG SG11201906427QA patent/SG11201906427QA/en unknown
- 2018-01-09 JP JP2019538585A patent/JP2020506903A/ja not_active Withdrawn
- 2018-01-18 TW TW107101775A patent/TWI665199B/zh not_active IP Right Cessation
- 2018-01-22 US US15/876,698 patent/US20180208608A1/en not_active Abandoned
-
2019
- 2019-06-03 US US16/429,678 patent/US10858373B2/en active Active
- 2019-07-01 IL IL267781A patent/IL267781A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190097242A (ko) | 2019-08-20 |
| WO2018134698A1 (en) | 2018-07-26 |
| EP3571202B1 (en) | 2021-06-30 |
| IL267781A (en) | 2019-09-26 |
| US20190292203A1 (en) | 2019-09-26 |
| TWI665199B (zh) | 2019-07-11 |
| TW201838995A (zh) | 2018-11-01 |
| JP2020506903A (ja) | 2020-03-05 |
| US20180208608A1 (en) | 2018-07-26 |
| CA3050853A1 (en) | 2018-07-26 |
| RU2726631C1 (ru) | 2020-07-15 |
| BR112019014099A2 (pt) | 2020-02-11 |
| AU2018208848A1 (en) | 2019-07-18 |
| SG11201906427QA (en) | 2019-08-27 |
| EP3571202A1 (en) | 2019-11-27 |
| US10858373B2 (en) | 2020-12-08 |
| CN110198944A (zh) | 2019-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019008690A (es) | Compuestos espiro heterociclicos como inhibidores de magl. | |
| PH12018500087A1 (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors | |
| MX2019008626A (es) | Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-ilcarbamato como inhibidores de monoacilglicerol lipasa (magl). | |
| GEP20217248B (en) | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh | |
| MX386258B (es) | Derivados de 5,7-dihidro-pirrolo-piridina para tratar enfermedades neurologicas y neurodegenerativas | |
| JOP20190151A1 (ar) | مركبات أمينو - ترايازولو بيريدين واستخدامها في علاج سرطان | |
| SA518391624B1 (ar) | Ror- منظمات جاما | |
| MX2019015371A (es) | Derivados de dihidro-pirrolo-piridina. | |
| MX388749B (es) | Compuestos de imidazo-piperidina fusionada que contienen una amida heterocíclica de 4 miembros como inhibidores de jak. | |
| SA518392101B1 (ar) | ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ | |
| GEP20227446B (en) | New catecholamine prodrugs for use in treatment of parkinson's disease | |
| PH12018500958A1 (en) | Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer | |
| MX2020013099A (es) | Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina. | |
| MY199446A (en) | Compounds and compositions and uses thereof | |
| PH12018500957A1 (en) | Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer | |
| GEP20196949B (en) | 2-amino-6-(difluoromethyl)-5, 5-difluoro-6-phenyl-3, 4, 5, 6-tetra- hydropyridines as bace1 inhibitors | |
| SA519401322B1 (ar) | مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2 | |
| PH12016502394A1 (en) | 1, 3, 4-thiadiazole compounds and their use in treating cancer | |
| PH12019500198A1 (en) | Compounds and compositions and uses thereof | |
| EA202091604A1 (ru) | Ингибирование ионного канала a1 с транзиторным рецепторным потенциалом | |
| MX377032B (es) | Compuestos de dihidroquinolinsulfonamida de alquilo. | |
| MX2021000549A (es) | Compuestos espiro heterociclicos como inhibidores de magl. | |
| MX2020008523A (es) | Compuesto que tiene actividad agonista del receptor esfingosina-1-fosfato [(2s,3r,4e)-2-amino-3-hidroxioctadec-4-enil- 1-fosfato (s1p5). | |
| MX2019014321A (es) | Compuestos biciclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias. | |
| JOP20190054A1 (ar) | مركبات إندازول للاستخدام في إصابات الأوتار و/ أو الرباط |